Appendix Table A10.
Distribution of Change in Symptom Survey Frequency Scores from Baseline for Individual Questionnaire Items at Follow-up Visits by Treatment Group.
| 4 weeksa | 8 weeksa | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Binocular Treatment | Continued Spectacles | Binocular Treatment | Continued Spectacles | |||||
|
|
||||||||
| N | % | N | % | N | % | N | % | |
|
| ||||||||
| Per Group (N) | 88 | 83b | 86 | 84 | ||||
|
| ||||||||
| Blurred Vision | ||||||||
| Increased frequency (≥ 2 levels) | 4 | 5% | 0 | 0% | 4 | 5% | 2 | 2% |
| Similar frequency (within 1 level) | 73 | 83% | 72 | 87% | 67 | 78% | 71 | 85% |
| Reduced frequency (≥ 2 levels) | 11 | 13% | 11 | 13% | 15 | 17% | 11 | 13% |
|
| ||||||||
| Eyestrain | ||||||||
| Increased frequency (≥ 2 levels) | 9 | 10% | 0 | 0% | 5 | 6% | 1 | 1% |
| Similar frequency (within 1 level) | 73 | 83% | 73 | 88% | 75 | 87% | 72 | 86% |
| Reduced frequency (≥ 2 levels) | 6 | 7% | 10 | 12% | 6 | 7% | 11 | 13% |
|
| ||||||||
| Headache | ||||||||
| Increased frequency (≥ 2 levels) | 7 | 8% | 0 | 0% | 5 | 6% | 0 | 0% |
| Similar frequency (within 1 level) | 76 | 86% | 72 | 87% | 76 | 88% | 77 | 92% |
| Reduced frequency (≥ 2 levels) | 5 | 6% | 11 | 13% | 5 | 6% | 7 | 8% |
|
| ||||||||
| Looking over spectacles c | ||||||||
| Increased frequency (≥ 2 levels) | 4 | 5% | 2 | 2% | 6 | 7% | 3 | 4% |
| Similar frequency (within 1 level) | 72 | 82% | 73 | 88% | 70 | 81% | 76 | 90% |
| Reduced frequency (≥ 2 levels) | 12 | 14% | 8 | 10% | 10 | 12% | 5 | 6% |
|
| ||||||||
| Taking off spectacles c | ||||||||
| Increased frequency (≥ 2 levels) | 1 | 1% | 0 | 0% | 0 | 0% | 2 | 2% |
| Similar frequency (within 1 level) | 78 | 89% | 80 | 96% | 76 | 88% | 77 | 92% |
| Reduced frequency (≥ 2 levels) | 9 | 10% | 3 | 4% | 10 | 12% | 5 | 6% |
The exact Wilcoxon rank sum test was used to compare the change in symptom frequency from baseline to 4 weeks (P = .35 for blurred vision; P < .001 for eyestrain; P = .002 for headache; P = .43 for looking over spectacles; P = .97 for taking off spectacles) and to 8 weeks (P = .97 for blurred vision; P = .02 for eyestrain; P = .01 for headache; P = .74 for looking over spectacles; P = .65 for taking off spectacles) between the treatment groups.
One participant in the control treatment group did not have a completed Symptom Survey at the 4-week visit.
There were no responses that spectacles were not worn.